OR WAIT null SECS
The need for lyophilization services is growing as a burgeoning pipeline of new biologics matures.
A growing pipeline of biologics that encompass therapeutic antibodies, proteins, and emerging therapies is driving the demand for more lyophilization. As a result, biopharmaceutical companies are increasingly outsourcing lyophilization operations to contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs). It is estimated that the market for lyophilization services for biopharmaceuticals will grow by 9.5% annually between 2017 and 2027, and that North America and Europe will continue to dominate the market over the next decade.
eBook: Outsourcing Resources, February 2020
When referring to this article, please cite it as F. Mirasol, “Lyophilization Services Gain Ground Amid Growing Biologics Market," BioPharm International Outsourcing ResourceseBook (February 2020).